Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
October 31 2024 - 4:05PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of: October 2024
Commission file number: 001-36578
ENLIVEX THERAPEUTICS LTD.
(Translation of registrant’s name into English)
14 Einstein Street, Nes Ziona, Israel 7403618
(Address of principal executive offices)
Indicate by check mark whether the registrant files or
will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Annual General
Meeting of Shareholders
On October 31,
2024, Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the “Company”), convened
its 2024 Annual General Meeting of Shareholders (the “Annual Meeting”); however, due to the lack of a quorum, the Annual
Meeting was adjourned for one week. Accordingly, the Annual Meeting will be reconvened on Thursday, November 7, 2024, beginning at 7:00
p.m. Israel time, at the offices of the Company located at 14 Einstein Street, Nes Ziona, Israel 7403618.
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Enlivex Therapeutics Ltd. |
|
(Registrant) |
|
|
|
|
By: |
/s/ Oren Hershkovitz |
|
Name: |
Oren Hershkovitz |
|
Title: |
Chief Executive Officer |
|
|
|
Date: October 31, 2024 |
|
|
|
|
|
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Nov 2024 to Dec 2024
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Dec 2023 to Dec 2024